Clinical Trial Update: Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment [Phase 2]

View source ↗

Summary

Clinical trial update notes that a Phase 2 study evaluating the pharmacokinetics and pharmacodynamics of CPX-351 in acute leukemias and myelodysplastic syndrome…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CPX-351 (Vyxeos) (CPX-351)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Status: WITHDRAWN